Related Experiment Video
Updated: Mar 30, 2026
09:08
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
7.3K
Expression and Function of CD44 in Epithelial Ovarian Carcinoma
Joelle D Sacks1, Maria V Barbolina2
1Department of Biopharmaceutical Sciences, University of Illinois at Chicago, 833 S Wood Street, 335 College of Pharmacy Building, Chicago, IL 60612, USA. jsacks3@uic.edu.
Biomolecules
|November 17, 2015
Summary
CD44 glycoprotein is crucial in epithelial ovarian cancer progression and metastasis. Targeting CD44 offers a promising therapeutic strategy for this deadly gynecologic malignancy.
Area of Science:
- Oncology
- Molecular Biology
- Gynecologic Oncology
Background:
- Epithelial ovarian cancer (EOC) is a leading cause of cancer death in women.
- CD44, a cell surface glycoprotein, plays a role in cancer cell adhesion, migration, and survival.
- Its involvement in EOC pathogenesis and progression is increasingly recognized.
Purpose of the Study:
- To review recent findings on CD44 expression and function in epithelial ovarian carcinoma.
- To highlight CD44's role in peritoneal adhesion, metastatic progression, and cancer stem cells.
- To discuss current therapeutic strategies targeting CD44 in EOC.
Main Methods:
- Literature review of recent studies on CD44 in epithelial ovarian cancer.
- Analysis of functional data regarding CD44's role in metastasis and stemness.
- Synthesis of information on CD44-targeted therapies.
Main Results:
- CD44 expression is linked to EOC progression and poor outcomes.
- CD44 influences peritoneal metastasis and cancer stem cell populations.
- Therapeutic targeting of CD44 shows potential in preclinical models.
Conclusions:
- CD44 is a significant factor in epithelial ovarian cancer progression and metastasis.
- CD44 represents a viable therapeutic target for EOC treatment.
- Further research into CD44-targeted therapies is warranted.
